Background: Conversional bariatric surgery inherently has less weight loss (WL) compared to primary procedures. Adjunctive use of the GLP-1 analog, liraglutide with conversional Roux-en-Y Gastric Bypass (cRYGB) may maximize the WL benefits of surgery.
Material And Methods: This single-center randomized double-blind placebo-controlled trial included 80 patients randomized into two groups; the liraglutide group (40 patients) who received daily injections of liraglutide, and the placebo group (40 patients) who received normal saline starting at 6 weeks from cRYGB and continued for 6 months. After discontinuing the drugs at 6 months and unblinding, the patient were followed up to 12 months. The endpoints were percentage of total weight loss (%TWL) and percentage of excess weight loss (%EWL), and changes in the metabolic biomarkers, and complications within 30 and 90 days according to the global outcome benchmark (GOB) stratification.
Results: In total, 38 patients in the liraglutide group and 31 in the placebo group completed the 24 weeks. Liraglutide group experienced better WL with a significantly higher mean %TWL at 1 month (10.27±1.39 vs. 8.41±2.08), at 6 weeks (12.65±1.77 vs. 10.47±2.23), at 6 months (18.29 ±1.74 vs. 15.58 ±1.65), and at 12 months 24.15±2.35 versus 22.70±2.13 (all P <0.001). For %EWL, this was also significantly higher in the liraglutide group at all time points. A %TWL of greater than 20% at 6 months of treatment was recorded in six (15.8%) patients in the liraglutide group and none in the placebo group ( P =0.029). Both groups had comparable changes in metabolic biomarkers. Adverse events were recorded in 11 (27.5%) patients in the liraglutide, with no adverse events in the placebo group ( P <0.001). Both groups had Clavien-Dindo scores I and II (5.0 and 2.5%), and GOB values indicated that 90.0 and 97.5% were low-risk patients.
Conclusion: Adjunctive use of liraglutide with cRYGB gives significantly higher WL and resolution of associated medical problems.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10942244 | PMC |
| http://dx.doi.org/10.1097/JS9.0000000000000990 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Effect of Pediatric Obesity Treatment on Long-Term Health.
JAMA Pediatr
January 2025
Division of Pediatrics, Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden.
Importance: Data regarding the long-term impact of treating childhood obesity on the risk of obesity-related events, including premature mortality, are limited.
Objective: To evaluate the long-term effect of different responses to pediatric obesity treatment on critical health outcomes in young adulthood.
Design, Setting, And Participants: The study included a dynamic prospective cohort of children and adolescents with obesity within The Swedish Childhood Obesity Treatment Register (BORIS) and general population comparators, linked with national registers.
Augmentation in corrosion inhibition efficiency in gram-negative bacterial strains influenced adsorption of Saccharum officinarum bagasse extract at the interphase of copper metal and a mild corrosive environment.
Environ Sci Pollut Res Int
January 2025
Department of Chemistry, Banasthali Vidhyapith, Banasthali, Rajasthan, 304022, India.
Plant extracts and bacterial biofilm are acknowledged to offer impressive corrosion-inhibitory activities. However, anticorrosive properties of their combination are still less reported. Thus, in the present study, we aimed to evaluate the corrosion inhibition efficiency of Saccharum officinarum bagasse (SOB) plant extract, Pseudomonas chlororaphis (P.
View Article and Find Full Text PDF[Diabetes mellitus and obesity: risk optimization before surgical interventions].
Orthopadie (Heidelb)
January 2025
Westdeutsches Diabetes- und Gesundheitszentrum, Verbund Katholischer Kliniken Düsseldorf, Hohensandweg 37, 40591, Düsseldorf, Deutschland.
Background: The prevalence of obesity has increased significantly in recent years and is a causal risk factor for the development of type 2 diabetes. Moreover, chronic degenerative joint diseases are also triggered by obesity.
Weight Loss: Both obesity-related secondary diseases-type 2 diabetes and chronic degenerative joint disease-can be prevented or at least delayed by lifestyle intervention aimed at weight reduction.
Tailoring Exercise Prescription for Effective Diabetes Glucose Management.
J Clin Endocrinol Metab
January 2025
Department of Kinesiology and Health, Rutgers University, New Brunswick, NJ 08901, USA.
Context: Physical activity, exercise, or both are a staple of lifestyle management approaches both for type 1 diabetes mellitus (T1DM) and type 2 diabetes (T2DM). While the current literature supports both physical activity and exercise for improving glycemic control, reducing cardiovascular risk, maintaining proper weight, and enhancing overall well-being, the optimal prescription regimen remains debated.
Evidence Acquisition: We searched PubMed and Google Scholar databases for relevant studies on exercise, insulin sensitivity, and glycemic control in people with T1DM and T2DM.
Mechanistic Insights into the Eco-Friendly Conifer Cone Extract's Corrosion Inhibition on Steel Rebar and Cement Mortar: An Experimental and Simulation Approach.
Langmuir
January 2025
Department of Robotics Engineering, Hanyang University, 55 Hanyangdaehak-ro, Ansan, Gyeonggi-do 15588, Republic of Korea.
This study investigates the corrosion inhibition effects of eco-friendly conifer cone extract (CCE) on steel rebars embedded in cement mortar exposed to 3.5% NaCl under alternate wet/dry cycles. CCE concentrations of 0, 0.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!